Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.

X. Carbonell-Estrany; L. Giuffre; J.L.L. Kimpen; D. Adam; N.H. Valerius; H. Devlieger; B. Shaw; W. Muller; O. Ruuskanen; O. Cunha; H.C. Meissner

Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.

Translated title of the contribution: Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.

X. Carbonell-Estrany, L. Giuffre, J.L.L. Kimpen, D. Adam, N.H. Valerius, H. Devlieger, B. Shaw, W. Muller, O. Ruuskanen, O. Cunha, H.C. Meissner

Integral pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.
Original language	Undefined/Unknown
Pages (from-to)	29-33
Number of pages	5
Journal	Infections in Medicine
Volume	16
Publication status	Published - 1999

Cite this

Carbonell-Estrany, X., Giuffre, L., Kimpen, J. L. L., Adam, D., Valerius, N. H., Devlieger, H., Shaw, B., Muller, W., Ruuskanen, O., Cunha, O., & Meissner, H. C. (1999). Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion. Infections in Medicine, 16, 29-33.

@article{9048cc2390af4e418c71d7694ab9857b,

title = "Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.",

author = "X. Carbonell-Estrany and L. Giuffre and J.L.L. Kimpen and D. Adam and N.H. Valerius and H. Devlieger and B. Shaw and W. Muller and O. Ruuskanen and O. Cunha and H.C. Meissner",

year = "1999",

language = "Undefined/Unknown",

volume = "16",

pages = "29--33",

journal = "Infections in Medicine",

issn = "0749-6524",

publisher = "CMP Healthcare Media LLC",

}

Carbonell-Estrany, X, Giuffre, L, Kimpen, JLL, Adam, D, Valerius, NH, Devlieger, H, Shaw, B, Muller, W, Ruuskanen, O, Cunha, O & Meissner, HC 1999, 'Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.', Infections in Medicine, vol. 16, pp. 29-33.

Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion. / Carbonell-Estrany, X.; Giuffre, L.; Kimpen, J.L.L. et al.
In: Infections in Medicine, Vol. 16, 1999, p. 29-33.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion.

AU - Carbonell-Estrany, X.

AU - Giuffre, L.

AU - Kimpen, J.L.L.

AU - Adam, D.

AU - Valerius, N.H.

AU - Devlieger, H.

AU - Shaw, B.

AU - Muller, W.

AU - Ruuskanen, O.

AU - Cunha, O.

AU - Meissner, H.C.

PY - 1999

Y1 - 1999

M3 - Article

SN - 0749-6524

VL - 16

SP - 29

EP - 33

JO - Infections in Medicine

JF - Infections in Medicine

ER -